Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.
Entasis Therapeutics, the former anti-infectives unit of AstraZeneca, has positive Phase 3 data for its lead program, an antibiotic that could address drug-resistant strains of Acinetobacter baumannii that contribute to hospital-acquired infections. The biotech plans to seek FDA approval in 2022.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Melinta Therapeutics already sells an antibiotic for serious skin infections. But FDA approval of Kimyrsa gives clinicians another option to offer patients, one with more convenient dosing.
Advocates, industry leaders and legislators have come to a consensus about the scope and urgency of the crisis related to inadequate development of antibiotics. They are calling for legislative fixes to protect public health.
The company is developing phage-based therapies designed to target specific bacteria strains, as contrasted with antibiotics, which target multiple types of bacteria.
Shares of the company were up more than 13 percent on the Tel Aviv Stock Exchange following the approval of Talicia, meant to address the growing issue of the bacteria's resistance to antibiotics. H. pylori is a major cause of gastric cancer.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Recarbrio was approved for treating complex urinary tract and intra-abdominal infections among adult patients who have limited or no therapy options.
In the wake of Achaogen's bankruptcy, experts discussed ways to ensure new treatments are available to combat drug-resistant bacteria that threaten a post-antibiotic world.
With New Enterprise Associates at the helm of the round, the company is setting out to develop antibiotics for drug-resistant bacterial infections.
Executive from urgent care-focused medical records firm says study numbers miss some of the nuances.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The ultimate goal of MeMed is to right-size antibiotic use. The team is working on a second-generation platform that gets results in minutes and that anyone can use.
CARB-X, the international antimicrobial consortium, has given a financial boost to 11 startups in the war against drug-resistant bacteria.
With the help of the 2012 GAIN Act, Zavante Therapeutics is breathing new life into a decades-old antibiotic.
It's good news and bad news on the acne front, based on two Phase 3 readouts delivered Monday.
One goal of the simulation platform, developed by Kognito, is to improve the quality of interactions between patients and physicians.